Company Revenue

The company declined in the double digits for 1Q22 as it continues the early commercialization efforts of its HOLO platform....

The company's orthopedic sales grew 9% organically in 1Q22 as Bioventus targets double-digit organic growth for the full year....

The company grew more than 55% in 1Q22 on the strength of its narrow procedure focus and expanding direct sales...

The company grew in the high single-digits during a better than expected 1Q22 and restated its full-year guidance for MACI....

The company grew in the low-teens for 1Q22 as procedures rebounded, but its ongoing business model transition incurred higher costs....

The company grew 25% in the first quarter of 2022 on the strength of its expanding portfolio, salesforce and surgeon...

The company grew in the low double digits for the first quarter of 2022 based on favorable order timing in...

The company grew in the low single digits for 1Q22 due to a tough comparison and a stagnant robotic sales...

The company grew over 60% in 1Q21 as recent acquisitions added momentum to Enovis' already impressive share gains....

The company grew over 20% in the first quarter of 2022 as it wins over new surgeons and more exclusive...